Nest 5 mL Sterile Disposable Sampler Tubes with Caps on 619011 USP VI Polypropylene Tubes, HDPE Caps. Self-standing: the vial placed on the lab workbench steadily even without a base. Electron Beam Sterilization, SAL=1-6: safe, fast, environment-friendly, no...
Vactosertib (CAS No.: 1352608-82-2), is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM.. >99% Purity. Synonyms: EW-7197, TEW-7197, EW7197, TEW7197, ALK5 inhibitor, ATP-competitive activin receptor-like kinase...
Nazartinib (EGF-816) (CAS No.: 1508250-71-2), a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. >98% Purity. Synonyms: EGF-816, EGF816, EGFR inhibitor, epidermal growth factor receptor inhibitor For...
RTA-408 (CAS No.: 1474034-05-3), a Novel Synthetic Triterpenoid That Binds to Kelch-like ECH-associated Protein 1 (Keap1) and Attenuate Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Degradation. >99% Purity. Synonyms: Omaveloxolone, Nuclear Factor Erythroid 2-Related Factor 2, Nrf2,...
KB0742 (KB-0742, KB 0742) (CAS No.: 2416874-75-2), an orally bioavailable, potent and selective CDK9 inhibitor with an IC50 of 6 nM, highly selective against other CDKs (>60 fold). 99% Chem and Optical Purity. Synonyms: KB-0742, KB 0742,...
The cheapest research grade toralizumab biosimilar (anti-human CD40L/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
The cheapest research grade ruplizumab biosimilar (anti-human CD40L/CD40/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
TAK-931 (CAS No.: 1330782-76-7), A Selective and ATP-Competitive Cell Division Cycle 7 (CDC7) Kinase Inhibitor. Synonyms: cell division cycle 7 inhibitor TAK-931, Simurosertib, TAK931, CDC7 kinase inhibitor
Background Information: Abstract (Ref 1): Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altiratinib inhibits not only mechanisms of tumor initiation and...
